PERFORMANCE IN INITIATING CLINICAL RESEARCH (Q1, 2015/16)

Research Ethics Committee Reference Number	Name of Trial	Date of Receipt of Valid Research Application	Date of First Patient Recruited	Benchmark Met?	Reason for not meeting benchmark
09/H1005/28	Molecular genetics of adverse drug reactions: from candidate genes to genome wide association studies.	31/10/2014	02/12/2014	Yes	Benchmark met
11/NW/0246	A Randomised Multi-Stage Phase II/III Trial of Standard first-line therapy (sunitinib or pazopanib) Comparing Temporary Cessation with Allowing Continuation, in the treatment of locally advanced and/or metastatic Renal Cancer	01/04/2015	20/04/2015	Yes	Benchmark met
12/LO/1177	Streamlining Staging of Lung Cancer with Whole Body MRI	27/10/2014	08/12/2014	Yes	Benchmark met
12/LO/1966	A Phase 3, Randomized, Placebocontrolled, Parallelgroup, Multicenter, Doubleblind Study to Evaluate the Efficacy and Safety of Telotristat Etiprate (LX1606) in Patients with Carcinoid Syndrome Refractory to Somatostatin Analog (SSA) Therapy	01/08/2014	14/08/2014	Yes	Benchmark met
12/WM/0199	A pragmatic randomised controlled trial assessing the impact of a low calorie Cambridge based diet programme (CDBP) on weight loss in obese patients with Type 2 diabetes mellitus treated with insulin	15/10/2014	04/11/2014	Yes	Benchmark met
12/WM/0373	A randomised trial in new hearing aid users to measure the benefit of using 4 pre-set configurations of hearing aids with self learning characteristics	04/11/2014	14/11/2014	Yes	Benchmark met
12/YH/0504	Assessment of the efficacy and safety of a new wound dressing in the local treatment of diabetic foot ulcers: A Prospective, randomised, controlled, doubleblind, European multicentre clinical trial.	12/02/2015	31/03/2015	Yes	Benchmark met
13/EM/0395	Treatment of Advanced Glaucoma Study (TAGS): A multicentre randomised controlled trial comparing primary medical treatment with primary augmented trabeculectomy for people with newly diagnosed advanced glaucoma	11/09/2014	03/11/2014	Yes	Benchmark met
13/EM/0460	A RANDOMIZED, MULTICENTER, OPEN-LABEL TRIAL COMPARING CHEMOTHERAPY PLUS TRASTUZUMAB PLUS PERTUZUMAB VERSUS CHEMOTHERAPY PLUS TRASTUZUMAB EMTANSINE PLUS PERTUZUMAB AS ADJUVANT THERAPY IN PATIENTS WITH OPERABLE HER2 POSITIVE PRIMARY BREAST CANCER	12/08/2014	20/10/2014	Yes	Benchmark met
13/LO/0326	A RANDOMIZED, PHASE 3 STUDY OF GANETESPIB IN COMBINATION WITH DOCETAXEL VERSUS DOCETAXEL ALONE IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG ADENOCARCINOMA	09/01/2015	10/03/2015	Yes	Benchmark met
13/LO/1224	Assessing sensitivity to and tolerability of intravenous psilocybin in patients with treatment-resistant depression: A Pilot Study	12/03/2015	21/04/2015	Yes	Benchmark met
13/LO/1463	An International Multicentre Open Label Randomised Phase II Advanced Anal Cancer Trial Comparing Cisplatin plus 5-fluorouracil versus Carboplatin plus Weekly Paclitaxel in Patients with Inoperable Locally Recurrent or Metastatic Disease	23/10/2014	22/12/2014	Yes	Benchmark met
13/LO/1595	COgnitive behavioural therapy vs standardised medical care for adults with Dissociative nonEpileptic Seizures: A multicentre randomised controlled trial.	31/10/2014	03/12/2014	Yes	Benchmark met
13/LO/1775	The PRAETORIAN Trial: A prospective, randomised comparison of subcutaneous and transvenous implantable cardioverter defibrillator therapy	26/11/2014	08/12/2014	Yes	Benchmark met
13/LO/1814	A phase III, randomized, controlled, single-blind, multicentre, parallel arm trial to assess the efficacy and safety of Pergoveris? (follitropin alfa and lutropin alfa) and GONAL-f? (follitropin alfa)	30/06/2014	28/08/2014	Yes	Benchmark met
13/NS/0002	A multicentre randomised controlled trial of extracorporeal shockwave lithotripsy, as first treatment option, compared with direct progression to uretrosepctic treatment, for ureteric stones	19/09/2014	27/10/2014	Yes	Benchmark met
13/NW/0002	Prospective, randomised, controlled investigation comparing the safety and performance of 032-11 Surgical Haemostat 2g Applicator with FLOSEAL Hemostatic Matrix as an adjunctive haemostat in cardiac surgery and thoracic aortic surgery -VICTORY Study	10/12/2014	20/01/2015	Yes	Benchmark met

13/NW/0778	A double-blind, randomised, placebo-controlled, Phase II study to evaluate ProCervix efficacy to clear HPV 16 and HPV 18 infection in women with normal cytology or ASCUS/LSIL	11/08/2014	03/10/2014	Yes	Benchmark met
13/SW/0132	Male synthetic sling versus Artificial urinary Sphincter Trial for men with urodynamic stress incontinence after prostate surgery: Evaluation by Randomised controlled trial	01/10/2014	09/12/2014	Yes	Benchmark met
13/WM/0419	MAMMO-50: Mammographic surveillance in breast cancer patients aged 50 years and over	16/07/2014	19/09/2014	Yes	Benchmark met
13/WS/0056	Cancer and Venous Access (CAVA) A randomised controlled trial with associated qualitative research of venous access devices for the delivery of long-term chemotherapy	03/02/2015	24/03/2015	Yes	Benchmark met
13/YH/0162	Hyaluronic Acid Binding Sperm Selection - HABSelect	17/09/2014	12/11/2014	Yes	Benchmark met
13/YH/0317	Current Steering to Optimize Deep Brain Stimulation	02/10/2014	16/10/2014	Yes	Benchmark met
13/YH/0394	Multi-centre Randomised Controlled Trial of Angiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) withdrawal in advanced renal disease	30/04/2015	11/06/2015	Yes	Benchmark met
14/EE/0086	Neuromuscular Electrical Stimulation (NMES) in Patients with Intermittent Claudication	29/10/2014	09/12/2014	Yes	Benchmark met
14/EE/0188	The Effects of Electronic Cigarettes on the Microcirculation of the Hand	28/07/2014	27/08/2014	Yes	Benchmark met
14/EE/0193	Adjuvant benefit of Neuromuscular Electrical Stimulation (NMES) in Supervised Exercise in Patients with Intermittent Claudication	20/10/2014	08/12/2014	Yes	Benchmark met
14/EM/0121	An open label randomised multicentre controlled trial of RITUXImab and mycophenolate mofetil (MMF) without oral steroids for the treatment of LUPus nephritis	08/04/2015	15/05/2015	Yes	Benchmark met
14/EM/1302	Neuromuscular Electrical Stimulation for the treatment of Diabetic Peripheral Neuropathy.	13/02/2015	10/04/2015	Yes	Benchmark met
14/LO/0083	An Open Label Study Examining the Efficacy and Cardiovascular Risk of Immediate Versus Deferred Switch From a Boosted PI to Dolutegravir (DTG) in HIV Infected Patients With Stable Virological Suppression	22/09/2014	07/10/2014	Yes	Benchmark met
14/LO/0117	Ablation versus anti-arrhythmic therapy for reducing all hospital episodes from recurrent atrial fibrillation.	27/03/2015	22/04/2015	Yes	Benchmark met
14/LO/0121	A Phase II, Double Blind, Randomised, Placebo-Controlled Study of the AKT Inhibitor AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer	27/08/2014	07/10/2014	Yes	Benchmark met
14/LO/0339	The ACORN study: Coping and Relaxation in Pregnancy	04/11/2014	03/12/2014	Yes	Benchmark met
14/LO/0369	Determining the pathophysiological role of slow conduction channels identified by Ripple Mapping of the ventricular scar	30/07/2014	05/08/2014	Yes	Benchmark met
14/LO/0662	A HUMAN IN VIVO FEEDING STUDY OF THE BLOOD MONOCYTE RESPONSE TO DIETARY LIPID INTAKE	11/07/2014	05/08/2014	Yes	Benchmark met
14/LO/0665	A Phase III OpenLabel Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK5172/ MK8742 in TreatmentNa?ve Subjects with Chronic HCV GT1, GT4, GT5, and GT6 Infection who are on Opiate Substitution Therapy.	28/08/2014	10/09/2014	Yes	Benchmark met
14/LO/0717	A Multicenter Phase 3 Randomized Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukaemia.	19/09/2014	10/11/2014	Yes	Benchmark met
14/LO/0805	Predictors of response to treatment with iron and erythropoietin in dialysis anaemia	14/05/2015	07/07/2015	Yes	Benchmark met
14/LO/0824	A Double-Blind, Randomised, Placebo-Controlled Dose Escalation Study to Assess the Safety, Tolerability and Efficacy of Single and Multiple Doses of PP 1420 in Healthy Subjects.	15/08/2014	07/10/2014	Yes	Benchmark met
14/LO/0831	Quantitative test of the resynchronization hypothesis with development of tools for haemodynamic optimization and response quantification	03/10/2014	03/11/2014	Yes	Benchmark met
14/LO/0854	Electrical stimulation in peripheral arterial disease	15/08/2014	27/08/2014	Yes	Benchmark met

14/LO/0882	A PHASE III, OPEN-LABEL, MULTICENTER,RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF MPDL3280A (ANTI-PD-L1 ANTIBODY) COMPARED WITH DOCETAXEL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AFTER FAILURE WITH PLATINUM-CONTAINING CHEMOTHERAPY	05/08/2014	06/08/2014	Yes	Benchmark met
14/LO/1123	REBIRTH: Liver Regeneration: a singlecentre, prospective, randomised controlled trial comparing radiofrequency assisted liver partition with portal vein ligation (RALPP) with portal vein embolization (PVE)	11/08/2014	28/08/2014	Yes	Benchmark met
14/LO/1197	Phase IB open label study to assess the safety, pharmacokinetics and clinical activity of Acelarin (NUC-1031) given on days 1 & 8 with carboplatin on day 1, every three weeks for 6 cycles in participants diagnosed with recurrent ovarian cancer.	30/10/2014	27/11/2014	Yes	Benchmark met
14/LO/1381	A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Reformulated Raltegravir 1200 mg Once Daily versus Raltegravir 400 mg Twice Daily, Each in Combination with TRUVADA	10/11/2014	08/01/2015	Yes	Benchmark met
14/LO/1493	A phase IV open-label, multi-centre, randomised, dual-arm, pilot study to assess the feasibility of switching individuals receiving Efavirenz with continuing Central Nervous System (CNS) toxicity, to Dolutegravir	22/01/2015	12/03/2015	Yes	Benchmark met
14/LO/1727	Diffusion tensor imaging (DTI tractography) in the prostate: Roadmapping the neurovascular bundle prior to radical prostatectomy.	24/11/2014	26/01/2015	Yes	Benchmark met
14/LO/1728	A Phase Ib Open Label Study of the Safety and Tolerability of ME-344 Given in Combination with Topotecan (Hycamtin?) in Patients with Solid Tumors	03/03/2015	17/04/2015	Yes	Benchmark met
14/LO/1779	Incentive in Diabetic Eye Assessment by Screening (IDEAS) Trial	12/03/2015	19/03/2015	Yes	Benchmark met
14/LO/1833	Pilot study to evaluate diffusion weighted MRI (DWMRI) Whole Body MRI in relapsed Multiple Myeloma at 3T: test re test, early response assessment and exploratory imaging of renal function	16/02/2015	01/04/2015	Yes	Benchmark met
14/LO/1834	A Phase I randomised, placebo-controlled, double-blind, single and multiple ascending dose study of the tolerability and pharmacokinetics of GBT440 in healthy subjects and patients with Sickle Cell Disease	27/04/2015	28/05/2015	Yes	Benchmark met
14/LO/2044	The role of intrinsic cardiac autonomic nervous system in human arrhythmogensis	16/03/2015	21/04/2015	Yes	Benchmark met
14/LO/2060	A PROSPECTIVE MULTICENTRE STUDY OF EFFECTIVENESS OF RIPPLE MAPPING FOR ATRIAL TACHYCARDIA ABLATION	15/01/2015	02/02/2015	Yes	Benchmark met
14/LO/2078	A Phase 1, first in man, study to assess the safety, pharmacokinetic profile and antiretroviral efficacy of C34-PEG4-Chol, a novel peptide fusion inhibitor for the treatment of HIV-infection	26/02/2015	14/04/2015	Yes	Benchmark met
14/LO/2143	Measurement of low-energy stimulation in patients with atrial fibrillation	15/05/2015	11/06/2015	Yes	Benchmark met
14/NE/1062	PHOTOdynamic versus white light-guided treatment of non-muscle invasive bladder cancer: randomised trial of clinical and cost-effectiveness	18/03/2015	14/05/2015	Yes	Benchmark met
14/NE/1246	CUT*HIVTHER 001 - A randomized phase I/II study to assess the safety and immunogenicity of the DNAGTU vaccine administered by two novel routes compared to placebo in HIV-infected patients on antiretroviral therapy	14/04/2015	15/05/2015	Yes	Benchmark met
14/NW/0130	A randomised, double blind, multi-center, placebo-controlled study to evaluate the efficacy, safety, and tolerability of NT100 in pregnant women with a history of unexplained recurrent pregnancy loss (RPL)	31/07/2014	04/09/2014	Yes	Benchmark met
14/NW/0290	Registry of Deep Brain Stimulation with the VERCISE? System: Vercise DBS Registry	21/11/2014	21/01/2015	Yes	Benchmark met
14/NW/1027	Evaluation of Sorafenib in combination with local microtherapy guided by GdEOBDTPA enhanced MRI in patients with inoperable hepatocellular carcinoma	16/02/2015	01/04/2015	Yes	Benchmark met
14/NW/1354	Romiplostim in Thrombocytopenic Paediatric Patients with ITP	22/06/2015	07/07/2015	Yes	Benchmark met
14/SC/0027	A Phase I/IIa Sporozoite Challenge Study to Assess the Safety and Protective Efficacy of Concomitant Administration of the Combination Malaria Vaccine Candidate Regimen of RTS,S/AS01B + ChAd63 and MVA encoding ME-TRAP and also RTS,S/AS01B alone.	24/09/2014	41918	Yes	Benchmark met
14/SC/0084	Electrical Stimulation in Diabetic Foot Ulceration	10/07/2014	41893	Yes	Benchmark met
14/SC/0157	Prehospital Assessment of the Role of Adrenaline: Measuring the Effectiveness of Drug administration In Cardiac arrest	27/11/2014	41999	Yes	Benchmark met

14/SC/0262	A Phase IV, prospective, open-label, uncontrolled, European Study in patients with neovascular Age-related macular degeneration (nAMD), evaluating the efficacy and safety of switching From intravitreal Aflibercept to RanIbizumab 0.5mg: SAFARI study	07/01/2015	42073	Yes	Benchmark met
14/SC/1014	A Randomized, DoubleBlind, Phase 3 Study of the JAK1/2 Inhibitor, Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas (The JANUS 1 study)	17/12/2014	20/01/2015	Yes	Benchmark met
14/SC/1206	The Efficacy and Cost effectiveness of Real Time Ultrasound Elastography in The Investigation Of Thyroid Nodules and the diagnosis of thyroid cancer.	09/03/2015	21/04/2015	Yes	Benchmark met
14/SW/0091	Randomized, DoubleBlind, Multicenter, Phase 3 Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous NonSmall Cell Lung Cancer (NSCLC)	30/10/2014	06/01/2015	Yes	Benchmark met
14/WM/0057	Bypass vs. Angioplasty in Severe Ischaemia of the Leg: Multicentre randomised controlled trial to compare the clinical and costeffectiveness of a ?vein bypass first? with a ?best endovascular first? revascularisation strategy	08/12/2014	31/01/2015	Yes	Benchmark met
14/WM/0159	Safety of Nasal Influenza Immunisation in Egg Allergic Children The SNIFFLE 2 study	02/10/2014	13/10/2014	Yes	Benchmark met
14/WM/0162	Barrier Enhancement for Eczema Prevention - BEEP	16/03/2015	01/04/2015	Yes	Benchmark met
14/WM/0185	Intranasal diagnostics in food allergy (INDY): a feasibility study	17/09/2014	27/10/2014	Yes	Benchmark met
14/WM/1055	A prospective, multicenter, randomized, double blind, placebocontrolled, 2parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with FOLFIRI to placebo in combination with FOLFIRI	09/03/2015	11/05/2015	Yes	Benchmark met
14/WM/1056	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects with Chronic HCV	05/09/2014	01/10/2014	Yes	Benchmark met
14/WM/1262	An Open Label Study of Sofosbuvir/GS5816 FixedDose Combination in Subjects with Chronic HCV Infection	23/03/2015	27/04/2015	Yes	Benchmark met
14/WS/1096	Uncovering obesity and diabetes related complex metabolic dysregulation associated to endometrial cancer	19/11/2014	15/01/2015	Yes	Benchmark met
14/YH/0047	Intraoperative raman spectoscopy for immediate human brain tumour diagnosis and detection of tumour margin	11/08/2014	02/10/2014	Yes	Benchmark met
14/YH/0049	A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of the Combined Lysis of Thrombus with Ultrasound and Systemic Tissue Plasminogen Activator (tPA) for Emergent Revascularization (CLOTBUST-ER) in Acute Ischemic Stroke.	08/08/2014	07/10/2014	Yes	Benchmark met
14/YH/0123	An Expanded Access Protocol for Idelalisib (GS-1101) in Combination with Rituximab for Relapsed, Previously Treated Subjects with Chronic Lymphocytic Leukemia.	08/07/2014	26/08/2014	Yes	Benchmark met
14/YH/1057	A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks with Sofosbuvir and Ribavirin for 24 Weeks in Subjects with Chronic Genotype 3 HCV Infection	29/08/2014	19/09/2014	Yes	Benchmark met
14/YH/1153	An Open-Label, Extension Study of the Effects of Leuco-methylthioninium bi (hydromethanesulfonate) in Subjects with Alzheimer?s Disease or Behavioral Variant Frontotemporal Dementia	18/11/2014	08/01/2015	Yes	Benchmark met
15/LO/0087	A Phase I, Storer Design, openlabel, crosssectional, single site trial of ANX776 in healthy volunteers, progressive glaucoma/glaucomasuspect/ ocular hypertensive subjects and nonarteritic anterior ischaemic optic neuropathy subjects	16/04/2015	02/06/2015	Yes	Benchmark met
15/LO/0181	A multicentre randomised controlled trial of compression therapy following endovenous thermal ablation of varicose veins	30/04/2015	18/05/2015	Yes	Benchmark met
15/LO/0210	An exploratory, open-label, multicenter study to evaluate the safety and efficacy of ATIR, donor T-lymphocytes depleted ex vivo of host alloreactive T-cells, in patients with a hematologic malignancy, who received a CD34-selected (..) cell	13/04/2015	30/04/2015	Yes	Benchmark met
15/LO/0227	The Sono-VE Study: Assessing the acceptability and feasibility of transperineal ultrasound and developing an ultrasound based predictive model for labour outcome; the sonopartogram.	14/04/2015	22/04/2015	Yes	Benchmark met
15/LO/0287	Boiled Oral Peanut Immunotherapy for the treatment of Peanut Allergy	05/05/2015	23/06/2015	Yes	Benchmark met
15/SC/0108	A Phase Ia clinical trial to assess the safety and immunogenicity of MVA-EBO Z alone and a heterologous prime-boost immunisation with ChAd3-EBO Z and MVA-EBO Z in healthy UK volunteers	21/05/2015	15/06/2015	Yes	Benchmark met

15/WS/0037	A single-arm, post-market study of the Endo GI Reinforced Reload with Tri-Staple Technology	24/04/2015	05/05/2015	Yes	Benchmark met
10/H0302/51	Improving the management and control of tuberculosis among hard to reach groups	09/02/2015	21/04/2015	No	Patients being seen and consented but none found eligible prior to 70 days. First patient screened 1 day after deadline.
12/EE/0029	A 12 week, single centre, open label study to evaluate the effect of fesoterodine flexible dosing regimen on the sexual function of women with overactive bladder.	22/01/2015	07/04/2015	No	Required complex / lengthy interviews with patients; due to personal details required, many patients either refused to consent or withdrew.
12/EE/0230	RITAZAREM: Rituximab vasculitis maintenance study - An international, open label, randomised controlled trial comparing rituximab with azathioprine as maintenance therapy in relapsing ANCAassociated vasculitis	14/04/2015	02/07/2015	No	Rare disease study.
12/SS/0138	REstart or STop Antithrombotics Randomised Trial - RESTART	29/05/2014	07/05/2015	No	Yet to recruit despite daily screening. Restrictive study exclusion criteria.
12/SW/0264	Pulmonary Arterial Hypertension: Working on Anxiety and Stress	06/08/2014	15/01/2015	No	Rare disease.
13/EE/0444	Maximizing CRT Delivery by using Multipolar Coronary Sinus Lead Acuity x4	05/02/2014	24/07/2014	No	Lengthy budget/contract negotiation.
13/LO/0451	The United Kingdom Transcatheter Aortic Valve Implantation (UK TAVI) Trial. A multi-centre randomised controlled trial to assess the clinical effectiveness and cost-utility of TAVI, compared with conventional surgical aortic valve replacement	11/07/2014	24/04/2015	No	Study team actively screening for suitable patients but none consented; continuing to screen against current protocol.
13/LO/1115	UK Multicentre Open-label Randomised Controlled Trial Of IV Iron Therapy In Incident Haemodialysis Patients	10/06/2014	20/08/2014	No	First patient consented before 70-days, but was ineligble. First eligible patient was recruited just one day after deadline.
13/LO/1233	MAGnetic NAnoparticle thermoaBLATion Retention and Maintenance in prostatE: A Phase 0 Study in Men (MAGNABLATE I Trial)	04/08/2014	10/12/2014	No	Sponsor suspended study due to patient safety issue. First patient has subsequently been recruited immediately after suspension lifted.
13/LO/1323	The efficacy and safety of Ferriprox? for the treatment of transfusional iron overload in patients with sickle cell disease or other anaemias	05/06/2014	30/10/2014	No	SIV has been postponed due to a delay with delivery of IMP.
13/LO/1682	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients with Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian,	08/09/2014	15/12/2014	No	Eligible patients were identified and approached in under 70 days, but declined to take part.
13/NI/0143	Scheduling nab-paclItaxEl with GEmcitabine (SIEGE): Randomised phase II trial to investigate two different schedules of nab-paclitaxel (Abraxane) combined with gemcitabine as first line treatment for metastatic pancreatic adenocarcinoma	29/07/2014	31/10/2014	No	Rare disease study. Study team actively looking for patients.
13/WA/0117	A randomised phase II trial of Olaparib maintenance versus placebo monotherapy in patients with non-small cell lung cancer	06/10/2014	16/12/2014	No	Delays in site activation. ICHT still managed to quickly recruit first patient 4 days after Sponsor green light (missed benchmark by 1 day).
13/WS/0282	Prospective, single-arm, global multi-center study to evaluate treatment of obstructive superficial femoral artery and/or popliteal lesions wiht a novel paclitaxel coated percutaneous angioplasty ballon.	12/02/2014	02/10/2014	No	Regulatory approvals delay (MHRA). NHS Permission delayed due to change of CRO study management team which led to delays in contract approval. First patient not yet recruited - no suitable patients have been found despite screening.
13/YH/0152	A Randomised Trial of the FLAMSABU Conditioning Regimen in Patients with Acute Myeloid Leukaemia and Myelodysplasia Undergoing Allogeneic Stem Cell Transplantation	28/07/2014	13/11/2014	No	Delays in the procurement of Amsacrine (study drug). Drug only made available in the UK in October 2014. First patient then recruited in mid-November.
14/LO/0102	A First Time in Human, Double Blind, Randomised, Placebo Controlled Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Intravenous Doses of SNF472 in Healthy Male Volunteers	15/10/2014	03/02/2015	No	Study opened to recruitment but no eligible patients yet consented.
14/LO/0362	Prospective, randomized, placebo-controlled, double-blind, multicenter, parallel-group, 24-week study to assess the efficacy, safety and tolerability of macitentan in subjects with inoperable chronic thromboembolic pulmonary hypertension	07/07/2014	02/06/2015	No	Rare disease study.
14/LO/0521	A prospective, randomized, open label, two arm Phase III study to evaluate treatment free remission (TFR) rate in patients with Philadelphia positive CML after two different durations of consolidation treatment with nilotinib 300mg BID.	15/07/2014	19/01/2015	No	Site initiated by Sponsor on day 65. Also a rare disease study (affects 1 in 100,000).
14/LO/0600	Preventing Recurrent Gestational Diabetes Mellitus with Early Metformin Intervention	19/09/2014	27/01/2015	No	Participant identification more challenging than anticipated when study discussed at feasibility assessment due to changes in clinical pathways.
14/LO/0864	A double blind, randomised controlled trial to assess the efficacy of paravertebral blocks for analgesia after cardiac surgery	13/08/2014	27/10/2014	No	Patients have been seen but have not consented to join the study.

14/LO/0871	A randomised controlled trial of a duodenal sleeve bypass device (EndoBarrier) compared with standard medical therapy for the management of obese subjects with type 2 diabetes	12/11/2014	13/02/2015	No	Team started looking for patients immediately after gaining approval and 9 days later the first patient was screened and consented (28th November 2014). There were 7 screening failures over a 2 month period until first successful recruitment. The main reason for patients not being eligible was that their HbA1C levels were out of range even though their GP confirmed in their referral that these patients meet the inclusion criteria prior to attending the screening visit.
14/LO/1053	A Phase 3 Randomised double blind Active study Evaluating Memelotinib vs Ruxolitinib in subjects with primary Myelofibrosis (PMF) or Post-poly cythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)	28/08/2014	02/06/2015	No	Delays in supplying study drug. This study has not opened yet anywhere in the UK or Europe due to drug supply problems. ICHT is one of only two UK sites that have issued approval and are ready to start as soon as the drug is available. Expected activation for UK sites is end of Q1 2015.
14/LO/1428	A phase 3 multi-centre double-masked randomised controlled trial of adjunctive intraocular and periocular steroid (triamcinolone acetonide) versus standard treatment in eyes undergoing vitreoretinal surgery for open globe trauma	06/01/2015	21/05/2015	No	Very specific eligibility criteria, making this essentially a rare disease (relies on a very specific eye trauma patient coming into A&E; unpredictable and rare).
14/NW/0008	Golimumab: A Phase 4, UK Open Label, Single arm Study on its Utilization and Impact in Ulcerative Colitis	17/09/2014	12/12/2014	No	Patients being seen and consented but none yet found eligible.
14/NW/1076	Randomised Evaluation of Surgery with Craniectomy for patients Undergoing Evacuation of Acute Subdural Haematoma (RESCUE-ASDH) Study Short Title RESCUE-ASDH trial. Version 1.0	18/03/2015	16/07/2015	No	Sponsor recognised difficulty in recruiting patients and new protocol has now been approved by REC (eliminated two of the previous exclusion criteria as well as leniency on consent procedure).
14/WM/0170	A Phase 3, Randomized Study To Evaluate the Efficacy of Momelotinib versus Best Available Therapy in Anemic or Thrombocytopenic Subjects with Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis,	14/10/2014	19/02/2015	No	Myelofibrosis is a rare disease.
14/YH/0085	Front-Line therapy in CLL: Assessment of Ibrutinib + Rituximab.	26/09/2014	26/02/2015	No	Very rare disease study (0.6 in 10,000 in males & 0.4 in 10,000 in females).
10/H0801/67	Focal MR-Guided Focused Ultrasound Treatment of Localized Low-Risk Prostate Cancer: Feasiblity Study	11/06/2014		No	Study team actively screening for patients. No patients recruited yet.
12/NE/0343	Clarifying the management of men with recurrent urethral stricture: A pragmatic multicentre randomised superiority trial of open urethroplasty versus endoscopic urethrotomy	01/10/2014		No	Rare disease study.
13/LO/0150	A randomized, double blind, placebo-controlled, multicenter phase III study of regorafenib in patients with hepatocellular carcinoma (HCC) after sorafenib	21/08/2014		No	Rare disease study. 3 patients identified but all failed eligibility criteria.
13/LO/1227	A Multicenter, Randomized, DoubleBlind, PlaceboControlled, Phase III Study of ARN509 in Men with NonMetastatic (M0) CastrationResistant Prostate Cancer	16/04/2015		No	No patients yet seen.
13/NE/0126	An exploratory, randomised, doubleblind, controlled study to assess the effect of an Amino Acid Based Formula with a synbiotic blend on gut microbiota and stool in infants with suspected gastrointestinal Non IgE mediated cow's milk allergy - ASSIGN NEO.1.C/F	18/09/2014		No	Inclusion criteria difficult.
13/NI/0160	Management of myocardial injury After NoncArdiac surgGEry (MANAGE)	25/03/2015		No	Study team have screened numeorus patients, but they did not meet the inclusion criteria. One patient was eligible, but declined to take part.
13/NW/0714	ECASS-4: ExTEND - European Cooperative Acute Stroke Study-4 Extending the time for Thrombolysis in Emergency Neurological Deficits	03/02/2015		No	Delays in sending drug shipment. Once the site had drugs, they immediately started screening but were unable to recruit within the 7 days left before 70 day benchmark was due. All patients arriving through A+E / HASU have been screened and a log kept. No eligible patients have been identified yet. Two patients consented were found ineligible after screening.
13/SC/0157	ROMAZA: Phase I trial of combination therapy with romidepsin and azacitidine in patients with newly diagnosed, relapsed or refractory Acute Myeloid Leukaemia ineligible for conventional chemotherapy	16/06/2015		not yet expired	Benchmark not yet expired
13/SC/0559	A Phase 3, Randomized, Placebo-controlled, Multicenter, Double-blind Study to Evaluate the Safety and Efficacy of Telotristat Etiprate (LX1606) in Patients with Carcinoid Syndrome	17/09/2014		No	Delay with SIV; also a rare disease.
13/SC/0583	MATCHPOINT - MAnagement of Transformed CHronic myeloid leukaemia: POnatinib and INTensive chemotherapy: a dose-finding study.	26/06/2015		not yet expired	Benchmark not yet expired
13/WS/0172	A Phase 2, Open-Label Study of Rucaparib in Patients with Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	06/08/2014		No	Recruitment suspended by Sponsor (Oct 2014); due to re-open March 2015. ICHT site opened end of August 2014 but no eligible patients seen in the 2 month period before suspension.
14/EE/0192	Neuromuscular Electrical Stimulation (NMES) in patients with critical limb ischaemia	16/06/2015		not yet expired	Benchmark not yet expired

14/EM/0130	A Phase 3, Open-Label, Randomized Study of Quizartinib (AC220) Monotherapy vs. Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory to, or Relapsed after, First-Line Treatment	28/11/2014		No	Rare disease.
14/EM/0186	A Randomized Controlled Phase 3 Study of Oral Pacritinib versus Best Available Therapy in Patients with Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis	15/09/2014		No	Very rare disease study (less than 1 in 500,000).
14/EM/1059	A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura	05/02/2015		No	Rare disease study.
14/EM/1060	A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura	09/03/2015		No	Rare disease study.
14/LO/0673	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS 1101 (CAL-101) in Combination with Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia.	13/02/2015		No	Rare disease study.
14/LO/0865	A Phase 2, Multi-Center, Randomised, Double-Blind, Ascending-Dose, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of IgA Nephropathy	07/11/2014		No	Initial NHS permission excluded use of tissue bank to store patient samples. Study team decided to wait until full approval was in place before starting to recruit. Several patients have been approached since 9th Jan 2015 (63 days after valid submission) but declined to take part.
14/LO/1295	One Stop Vein Clinic - Evaluating the Feasibility and Acceptance of a One Stop Vein Clinic	26/05/2015		not yet expired	Benchmark not yet expired
14/LO/1864	The CNS Integrase Inhibitor Study	12/06/2015		not yet expired	Benchmark not yet expired
14/LO/1994	The AMARANTH study - A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled,Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease	18/06/2015		not yet expired	Benchmark not yet expired
14/LO/2103	Optimising effectiveness and minimising toxicity of intravenous salbutamol in children with acute asthma	26/05/2015		not yet expired	Benchmark not yet expired
14/LO/2196	A phase 2, double-blind, parallel group, randomised, placebo controlled, proof of concept study to assess the safety and efficacy of OBE001 after oral administration in pregnant women with threatened preterm labour	15/05/2015		not yet expired	Benchmark not yet expired
14/NE/1072	A PHASE II RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED BRONCHOSCOPY STUDY TO EVALUATE THE EFFECTS OF LEBRIKIZUMAB ON AIRWAY EOSINOPHILIC INFLAMMATION IN PATIENTS WITH UNCONTROLLED ASTHMA ON INHALED CORTICOSTEROIDS AND A SECOND CONTROLLER MEDICATION	16/01/2015		No	Delays in sponsor sending equipment needed for the study. Suitable volunteers have been approached but were either inegible or declined.
14/NW/0036	ESPAC 5 - Four arm, prospective, multicentre, randomised feasibility trial of immediate surgery compared with neoadjuvant chemotherapies and neoadjuvant chemoradiotherapy	12/03/2015		No	Rare disease study.
14/NW/1427	A Phase 3, Randomized Study Investigating the Safety of CVT-301 (Levodopa Inhalation Powder) in Parkinsons Disease Patients With Motor Response Fluctuations (OFF Phenomena) Compared to an Observational Cohort Control	29/04/2015		not yet expired	Benchmark not yet expired
14/SC/1056	A multicentre randomised controlled trial to compare the efficacy of ex-vivo oxygenated hypothermic machine perfusion with non-oxygenated hypothermic machine perfusion of kidneys older than 50 years of age and donated after circulatory death	04/03/2015		No	Not possible to recruit first participant due to lack of allocated organs for the study (site has no control over this national diseased organ allocation system and there is no way to predict if and when we will be allocated organs for the study.)
14/WM/0083	A Phase III Trial of Surgery versus Active Monitoring for Low Risk Ductal Carcinoma in Situ (DCIS)	06/03/2015		No	Rare disease study.
14/WM/1202	B0401016: A Phase 1b, Randomized, Double-Blind (Sponsor Open), Placebo-Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-04447943, (...) In Subjects With Stable Sickle Cell Disease	11/06/2015		not yet expired	Benchmark not yet expired
14/WS/1105	REVEAL 101MS408 Multicenter study of Natalizumab v Fingolimod in MS	26/03/2015		No	Delays in negotiating service support from MRI unit caused site recruitment to be suspended. Service provider's ECG machine - delayed set up. Site confirmed they are ready to start recruitment once equipment is in place.
14/YH/1234	A phase III, doubleblind, randomised study to assess the efficacy and safety of AZD9291 versus a standard of care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as firstline treatment in patients with (...) NonSmall Cell Lung Cancer	10/04/2015		No	Sponsor delays in giving site greenlight to start recruiting, and in providing imaging equipment and access to IWRS system needed to conduct the study.

15/LO/0140	CLEANER Assessment of efficacy and safety for a new wound dressing URGO 310 3166 in the local treatment of venous or mixed leg ulcers: a European, randomised clinical trial.	04/06/2015		not yet expired	Benchmark not yet expired
15/LO/0292	PILOT STUDY OF HOME ACTIGRAPHY MONITORING IN MS	01/04/2015		No	Specialist supplier did not deliver essential equipment to site which was due to arrive in early April. Sponsor has now ordered alternative equipment expected on or before 14 August.